Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge  by Kupczyk, Maciej et al.
Respiratory Medicine (2010) 104, 1404e1409ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedMediators of inflammation in nasal lavage from
aspirin intolerant patients after aspirin challengeMaciej Kupczyk a,*, Zofia Kurmanowska b, Izabela Kuprys-Lipinska a,
Ma1gorzata Bochenska-Marciniak b, Piotr Kuna aaDepartment of Internal Medicine, Asthma and Allergy, Medical University of Ło´dz, Kopcinskiego 22, 90-153 Ło´dz, Poland
bDepartment of Pneumonology and Allergy, Medical University of Ło´dz, Poland
Received 1 December 2009; accepted 16 April 2010
Available online 10 May 2010KEYWORDS
Aspirin (ASA)
hypersensitivity;
Aspirin challenge;
MCP-3;
RANTES;
EotaxinAbbreviations: ASA, aspirin; AIA, asp
leukotriene; Il, interleukin; MCP-3, mo
15-HETE, 15-hydroxyeicosatetraenoic
* Corresponding author. Tel./fax: þ
E-mail address: matiska@wp.pl (M
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.04.017Summary
The pathogenetic mechanisms underlying development of persistent inflammation in aspirin
(ASA) intolerance are not fully understood. The aim of this study was to determine levels of
MCP-3, RANTES, eotaxin, Il-5 and Il-3 in aspirin intolerant asthmatics (AIA) after nasal lysi-
neeaspirin (LyseASA) challenge. Twenty AIA and 10 aspirin tolerant controls (ATC) were chal-
lenged with saline or 14.4 mg of LyseASA. LyseASA challenge induced clinical symptoms and
influx of eosinophils and basophils only in AIA group. Statistically significant higher levels of
MCP-3 and RANTES were found in lavages from AIA as compared with ATC (p< 0.05 in all time
points). Before challenge the average level of MCP-3 was 86.95 pg/ml in AIA and 47.61 pg/ml in
ATC, RANTES levels were 34.20 pg/ml in AIA and 17.21 pg/ml in ATC and did not change after
the challenge in both group. The mean eotaxin’s level was 11.01 pg/ml in AIA and 8.03 pg/ml in
ATC before and increased to 20.06, 26.22 pg/ml (4 and 24 h in AIA) as compared to 10.51,
14.76 pg/ml (4 and 24 h in ATC) after the challenge (p< 0.05). Interleukin-3 and Il-5 were
not detectable. The highest inhibition of eosinophils’ chemotaxis was induced by anti-eotaxin
(47% of inhibition), followed by anti-RANTES (29%), anti-MCP-3 (19%) and anti-Il-5 (9%). In
summary, we found that persistent inflammation in AIA patients is characterized by overpro-
duction of MCP-3 and RANTES. Lack of increase in MCP-3 and RANTES levels after LyseASA chal-
lenge suggest that those mediators are involved in chronic rather than acute phase of ASA
induced inflammation.
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In some patients ingestion of aspirin (ASA) and other non-
steroidal anti-inflammatory drugs (NSAIDs) may trigger
asthma attack, symptoms of rhinosinusitis, urticaria and
angioedema. The prevalence of ASA intolerance in the
general population is estimated on 0.5e2.5% however, in
a group of asthmatics it is close to 10%.1,2 ASA intolerance is
an important factor associated with the development of
severe asthma.3 The mechanisms underlying this syndrome
are not fully understood. It has been proposed that inhibi-
tion of COX-1 by ASA and other non-selective NSAIDs may
shunt the metabolism away from the production of
protective prostanoids towards proinflammatory ones
including cysteinyl leukotrienes (Cys-LT). Other possible
mechanism can involve structural changes in COX-2 induced
by ASA. Another hypothesis claims that ASA induced accu-
mulation of 15-HETE results in diminished biosynthesis of
lipoxins (LX) which results in an imbalance between
protective and proinflammatory mediators.4 In one of our
previous study we have shown that lipoxins’ generation is
decreased in aspirin intolerant asthmatics (AIA) after ASA
challenge.5 However, it is still unclear why in the airways of
ASA intolerant patients despite avoiding triggering factors,
like ASA and other NSAIDs, we can still find signs of
persistent, severe inflammation with marked eosinophilia,
epithelial disruption, cytokine production and upregulation
of several adhesion molecules.6,7
The goal of our study was to evaluate levels of several
proinflammatory mediators, including MCP-3, RANTES,
eotaxin, Il-5 and Il-3 in nasal lavage fluid from AIA patients
in nasal lysineeaspirin (LyseASA) challenge in vivo model.
The results of such tests should add to our understanding of
chronic inflammation in ASA intolerance.
Methods
Study group
Twenty aspirin sensitive (AIA) and 10 aspirin tolerant controls
(ATC) were included into the study. ATC group consisted of 5
patients suffering fromallergic rhinitis and5healthy subjects.
Patients’ medical histories were studied, demographic and
clinical data were collected. The diagnosis of aspirin intoler-
ance has been confirmed with an oral aspirin challenge per-
formed during the 12 months directly preceding the study
according to accepted protocols.8 All ATC patients reported
use of nonsteroidal anti-inflammatory drugs (NSAIDs) without
anyadverseeffects. Baseline characteristicof the studygroup
is presented in Table 1. Patients with aspirin hypersensitivity
had statistically significant lower baseline FEV1 (forced
exhaled volume in first second) values (3.61 vs. 3.97, respec-
tively, pZ 0.048) and higher number of polypectomies (2.55
vs. 0.72, respectively, pZ 0.049) in comparison to ATA group.
All patients were non-smokers, in stable clinical condition.
Doses of asthma medications including inhaled steroids and
rescue drugs were not changed during the study. None of the
subjects had received any systemic steroids. Topical steroids
and oral antihistamines were withdrawn for at least 2 weeks,
antileukotrien drugse 1 week, nasal a-agonistse 48 h before
the challenge.Nasal challenge
Intranasal challenges and nasal lavages were performed as
in pilot study.5 Shortly, placebo (saline solution) or single
dose e 14.4 mg of lysineeaspirin (LyseASA) (Aspisol,
Bayer, Germany) (which is an equivalent to 16 mg of ace-
tylsalicylic acid) were aerosolized to both nostrils on
a consecutive day. Aspirin dose was selected basing on
other reports.9,10 Nasal lavages (6 ml of saline per nostril)
were collected before and then 1, 2, 4 and 24 h after
challenges as described by Greiff et al.11 A centrifugation
(10 min at 1000 rpm, 4 C) of saline washings separated cell
pellet and supernatant. Supernatant was immediately
frozen (80 C) for further analyses. The obtained sedi-
ment was washed in a sterile phosphate buffered saline
(PBS, Sigma) and then suspended in 1.0 ml of RPMI 1640
(Sigma). After staining the cells (Hansel’s method) the total
number of eosinophils and basophils (metachromatic cells)
was counted with the use of FuchseRosental chamber
allowing determination of the number of cells in 1.0 ml of
recovered fluid. Differential cell counts were performed on
slides stained by MayeGrunwaldeGiemsa method. A
minimum of 400 cells was counted per smear to enable
differential cell count to be made for each specimen. Cells
were classified according to their morphology as neutro-
phils, eosinophils, basophils, mononuclears and epithelial
cells. Epithelial cells were disregarded.
Clinical symptoms (rhinorhea, itching nose and eyes,
sneezing, blockage, post-nasal drip) were described by
patients before and after the challenge with visual
analogue scale (VAS)12 and then transferred to numerical
values (0 e minimum, 100 e maximum points for one
symptom, resulting in 600 points in total) for further anal-
yses. All other symptoms including but not restricted to
cough, dyspnoe, edema, adverse events and lung function
tests were also recorded.
Measurement of mediators
Mediators’ (MCP-3, RANTES, eotaxin, Il-5 and Il-3) levels
were determined in nasal lavage fluid at all time points
using commercially available ELISA kits (R&D Systems
Europe, Abingdon, UK). Methods’ detection limit were
1.01 pg/ml for MCP-3; 2.0 pg/ml for RANTES; 5.0 pg/ml for
eotaxin; 3.0 pg/ml for Il-5 and 7.4 pg/ml for Il-3.
Eosinophils’ isolation
Peripheral blood was obtained from AIA and ATC patients.
Eosinophils were isolated using histopaque gradient and
dextran sedimentation, then further purified by negative
selection using antibody coated paramagnetic beads
against CD16 (MACS System, Miltenyi Biotec GmbH). Eosin-
ophils purity was constantly greater than 97% and viability
was greater than 98%.
Chemotaxis assay
Eosinophils migration was measured in 48-well micro-
chemotaxis chamber (Neuroprobe Inc, USA) using a modified
Boyden’s method. Briefly, 30 mL of fLMP10-7 mol/l or PBS or
Table 1 Basic characteristic of the study group.
AIA ATC p
N 20 10 e
Age (years SD) 44.39 10.26 38.35 13.06 0.877c
Sex (F:M) 11:9 6:4 0.568a
Asthma 20 0 0.0001b
Atopyd 8 5 0.09b
FEV1 before challenge (l/min) 3.61 3.97 0.049c
FEV1 before challenge (%predicted) 75% 98% e
FEV1 1 h after challenge (l/min) 3.52 3.92 0.036c
FEV1 1 h after challenge (% predicted) 74% 97% e
Polypectomies (mean, median, minemax) 2.61 (0; 0e8) 0.76 (0; 0e2) 0.035c
a Chi-square test.
b Fisher’s test.
c ManneWhitney U test.
d Atopy defined as at least one positive result (3 mm) in skin prick tests with a basic allergen set.
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Figure 1 Eosinophils influx (%, SD) into nasal lavages after
aspirin intranasal challenge (*p< 0.05 placebo vs. LyseASA
challenge in AIA subjects, #p< 0.05 AIA vs. ATC group).
1406 M. Kupczyk et al.supernatants from 0 and 2nd hour after the ASA challenge
with or without antibodies were added to the bottom wells.
Anti-MCP-3 (1 mg/ml), anti-RANTES (7 mg/ml), anti-eotaxin
(5 mg/ml) and anti-Il-5 (5 mg/ml) antibodies (all manufac-
tured by Lenco Technologies Inc, St. Louis, USA) were added
and chemotaxis to supernatants was evaluated. Thirty
microliters of purified eosinophils (106/ml) suspended in
buffer were placed in the top wells. The chamber compart-
ments were separated by 5 mm pores policarbonate filter
without PVP. The chemotaxis chambers were subsequently
incubated for 120 min at 37 C in 5% CO2. Then filters were
removed, fixed and stained using LeukoStat Stain Kit (Fisher
Scientific, USA). Eosinophils thatmigrated across the filter to
its bottom side were counted using light microscopy
(magnification 400) in 20 high power randomly chosenfields
from each of 4 identical wells. For each assay the chemo-
tactic index (number of cells migrating to chemoattractant/
number of cells migrating to PBS) was calculated and
expressed as a mean value.
Statistical analysis
Collected data were analyzed using SPSS 17.0 (Chicago, IL,
USA) with chi-square test, Fisher’s test, Wilcoxon’s test
(within groups) and ManneWhitney’s U test for comparison
between the groups. p values of less than 0.05 were
considered as significant. The study protocol was approved
by the local ethic board of the Medical University of Lodz
(RNN/128/03/KE, dated 10.06.2003) and informed consent
was obtained from all subjects.
Results
Intranasal LyseASA challenge in ASA sensitive patients
induced rhinorhea, sneezing, nasal congestion, itching and
sometimes cough. One patient from AIA group complained
about dyspnoe with significant drop in FEV1 (D18.6%) after
ASA challenge. This resulted in treatment with nebulized
short acting b agonists (salbutamol) and oral steroids (a
single dose of 32 mg of methylprednisolone). Other adverse
events in AIA group after LyseASA challenge were mild and
did not require any medications. No adverse events were
reported by ATC subjects.Symptoms of clinically positive nasal challenge were
accompanied by influx of leukocytes to nasal secretions. As
we reported in our pilot study 5 the cells’ influx started
during 1st hour after provocation, reached maximum in 2nd
hour and prolonged in some cases to 24 h. Percentage of
eosinophils after LyseASA challenge increased in AIA
patients from 3.5% (mean basal value) to maximum of
17.05% in 2nd hour. Maximal spontaneous influx in placebo
day was observed also in 2nd hour and reached 6.9%
(Fig. 1). Percentage of basophils after LyseASA challenge
increased in AIA patients from 1.5% (mean basal value) to
maximum of 5.1% in 2nd hour. Maximal spontaneous influx
in placebo day was observed in 4th hour and reached 2.15%
(data not shown). The influx of both eosinophils and baso-
phils was significantly higher in AIA patients as compared
LyseASA to placebo challenge (p< 0.05) and in AIA as
compared to ATC group (p< 0.05).
Mediators’ levels
Statistically significant higher levels of MCP-3 and RANTES
were observed in lavages from AIA as compared with ATC
subjects (p< 0.05 in all time points). Before aspirin prov-
ocation the average level of MCP-3 was 86.95 pg/ml in AIA
and 47.61 pg/ml in ATC and did not change significantly
after provocation in both groups (Fig. 2). Before aspirin
provocation the average level of RANTES was 34.20 pg/ml in
AIA and 17.21 pg/ml in ATC group and did not change
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Figure 2 MCP-3 levels (mean SD) before and after intra-
nasal aspirin challenge (*p< 0.05 AIA vs. ATC after LyseASA
and placebo challenge).
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Figure 4 Eotaxin levels (mean SD) before and after intra-
nasal aspirin challenge (*p< 0.05 AIA vs ATC after LyseASA and
placebo challenge).
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found a statistically significant difference between eotaxin
levels in AIA and ATC groups only in 4 and 24 h time points
after the challenge. Before LyseASA challenge the mean
level of eotaxin was 11.01 pg/ml in AIA and 8.03 pg/ml in
ATC and increased to 20.06, 26.22 pg/ml (4 and 24 h in AIA)
as compared to 10.51, 14.76 pg/ml (4 and 24 h in ATC)
(p< 0.05) (Fig. 4). The levels of Il-3 and Il-5 in most time
points were close to the detection limit of the method
used, thus were not further analyzed.
Significant differences in levels of MCP-3 and RANTESmay
be regardedas auseful diagnostic tool to distinguishbetween
AIA and ATC. Further statistical analysis revealed that the
level of MCP-3 which enables differentiation between AIA
and ATC group was 38.3 pg/ml before and 38.7 pg/ml at 1 hr
time point during placebo challenge. The sensitivity and
specificity of these measurements were 80% and 85% before
and 89% and 100% at 1 hr time point. The level of RANTES
which enables differentiation between AIA and ATC group
was from 19.2 to 21 pg/ml depending on the time point
selected. The sensitivity and specificity of these measure-
ments were respectively 80% and 85% in majority of time
points.
Chemotactic activity
Chemotactic index of eosinophils to fMLP from AIA was
lower then from ATC (healthy and allergic sub-groups) and
counted respectively 1.75 in AIA, 3.6 in healthy and 6.3 in
allergic subjects. The highest inhibition of eosinophils’
chemotaxis was induced anti-eotaxin (47% of inhibition),
followed by anti-RANTES (29%), anti-MCP-3 (19%) and anti-
Il-5 (9% of inhibition).0
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Figure 3 RANTES levels (mean SD) before and after intra-
nasal aspirin challenge (*p< 0.05 AIA vs ATC after LyseASA and
placebo challenge).Discussion
LyseASA nasal challenge is accepted method for the diag-
nosis of ASA intolerance. Moreover, in contrast to oral and
bronchial challenges, it is a promising tool to study mech-
anisms of inflammation after local instillation of triggering
factor. In out previous study 5 we found that LyseASA
challenge is associated with increase in symptoms of
rhinitis and influx of eosinophils and basophils to nasal
lavage fluid in AIA patients. Statistically significant higher
levels of LTC4 were found in AIA in comparison to ATA group
at baseline and in 1st hour after the challenge. Simulta-
neously, the mean LXs’ levels decreased in AIA and
increased in ATA patients.
In this paper we evaluated production of several other
cytokines that may be of importance in inflammation in AIA
patients. We selected MCP-3, RANTES, eotaxin, Il-5 and Il-3
because of possible involvement of those mediators in
eosinophilic inflammation and lack of published reports
regarding their significance in ASA intolerance up to date.
We found significantly higher levels of MCP-3 and RANTES in
lavages from AIA as compared with ATC subjects in all time
points. MCP-3 (CCL7) is a chemotactic factor and an acti-
vator of several inflammatory cells, mainly monocytes, but
not neutrophils.13 RANTES (CCL5) is a member of inter-
leukin 8 superfamily and, similarly to MCP-3, is a potent
chemoatractant for monocytes and T cells.14 It seems likely
that in our model high levels of MCP-3 and RANTES in nasal
lavages mirror rather chronic inflammatory process taking
place in the mucosa of AIA patients, not the acute stage of
hypersensitivity reaction itself only, as we have not seen
any further increase in levels of those cytokines after
LyseASA challenge. Pods et al 15 evaluated RANTES mRNA
expression and protein production in nasal polyp tissue
specimens taken from patients suffering from chronic
sinusitis, asthma, aspirin intolerance and patient with
aspirin triad. In contrast to our findings, the expression of
RANTES mRNA and protein synthesis did not differ signifi-
cantly between the groups.
We found a statistically significant difference between
eotaxin levels in AIA and ATC groups only in 4 and 24 h time
points after the challenge. In another report eotaxin-2
mRNA was higher in patients with aspirin triad.15 In a study
by Min et al.16 plasma levels of eotaxin-2 were higher in ATA
than in AIA group after oral ASA challenge. Eotaxin (CCL11)
selectively recruits eosinophils by inducing their chemo-
taxis. It is synthesized by several cell types including airway
1408 M. Kupczyk et al.and vascular epithelium, airway smooth muscles, macro-
phages and eosinophils themselves. T-helper (Th)2
lymphocytes are known to produce interleukins Il-4 and Il-
13 which stimulate eotaxin production.17 In allergen expo-
sure animal model a peak of eotaxin production was
observed at 6 h after the challenge followed by a slow
decrease until 12 h. Eotaxin’s levels correlated with
eosinophils’ recruitment.18 In this study we observed
significant influx of eosinophils already at 1 h after the
challenge followed by an increase of eotaxin levels at 4 and
24 h. Thus, it seems that eotaxin is not the major chemo-
atractant for eosinophils in aspirin intolerant subjects after
ASA exposure. It is definitely more likely that cysteinyl
leukotrienes may be responsible for orchestrating acute
and chronic phase of inflammation in AIA. In our previous
study5 we found that LTC4 levels increased significantly
already at 1 h after LyseASA challenge, which correlates
clearly with influx of eosinophils. Other eicosanoids like
lipoxins and prostaglandins and imbalance between their
anti- and pro-inflammatory action, in aspirin intolerant
patients, may be of importance as well.5,19,20
To our surprise we have not found detectable levels of
Il-5 and Il-3 in nasal lavage fluids after LyseASA chal-
lenge. Interleukin 5 is a cytokine that stimulates B cells
growth and immunoglobulin production. Il-5 also
promotes differentiation of eosinophils’ progenitors,
enhances migration, survival and degranulation of
matured eosinophils.21 It has been found that Il-5
expression in bronchial tissue and BAL, as well as the
number of eosinophils and mast cells expressing Il-5 is
higher in AIA patients.22 Interleukin 3, similarly to gran-
ulocyte/macrophage colony stimulating factor (GM-CSF),
is released by activated T lymphocytes and stimulates
proliferation and differentiation of all cells in the
myeloid lineage. Mastalerz et a. 21 were able to detect
serum Il-5 in 12 of 43 asthmatics, using a method that
was slightly more sensitive in comparison to ours (1.5 pg/
ml vs. 3 pg/ml). Il-5 levels were higher in ATA (aspirin
tolerant asthmatics) not AIA patients. No relationship was
found between serum Il-5 and urinary cys-LT. Thus, it has
been concluded that overexpression of Il-5 in the airways
of AIA is not reflected in the blood. In another study Sun
et al. 23 evaluated eosinophilic cationic protein (ECP) and
Il-5 levels in nasal secretions of patients with nasal pol-
yposis with or without asthma and aspirin intolerance.
ECP levels correlated with Il-5, degree of tissue eosino-
philia and computed tomographic (CT) scores. Patients
without recurrent nasal polyps had significantly lower
levels of ECP in comparison to those with recurrence
which clearly shows association of disease severity with
underlying persistent inflammation.
We found that eosinophils isolated from peripheral blood
of AIA group have lower chemotactic activity to fMLP (mean
chemotactic index 1.75) than eosinophils from healthy
subjects (index 3.6) and allergic patients (index 6.3) which
could be explained by possible desensitization due to
chronic exposure to several factors at the inflammation
site. Similarly, in contrast to eosinophils from ATA patients
and healthy controls, eosinophils from AIA subjects are
relatively insensitive to in vitro stimulation with Il-5 prob-
ably due to previous in vivo overstimulation.24 Probable
mechanisms may involve lower expression orinternalization of Il-5 receptors. Among studied chemo-
tactic factors eotaxin was found to be the most important
chemoatractant in nasal lavages from AIA group, however
as it has been discussed above other mediators (including
cys-LT) may be of major role in vivo.
Our model of in vivo nasal LyseASA challenge ensures
relatively easy access to the nasal mucosa which is a site of
ongoing inflammation. The possible limitation of the study
is that detection of studied mediators was based only on
ELISA methodology and has not been confirmed with further
mass spectrometry analyses or determination of mRNA
expression. On the other hand ELISA is a valuable and
widely used method in detection of several mediators.
However, its limitations including cross-reactivity with
other molecules of similar structure and detection limits
should always be kept in mind.
In summary, we found that persistent inflammation in
upper airways of AIA patients is characterized by over-
production of MCP-3 and RANTES. There was no significant
increase in MCP-3 and RANTES levels after LyseASA chal-
lenge, thus we hypothesize that those mediators are
involved in chronic rather than acute phase of ASA induced
inflammation. Eotaxin levels followed rather than pro-
ceeded influx of eosinophils and were not influenced by
LyseASA challenge as well. Il-5 and Il-3 levels were below
the detection limit of the used method.
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